C8orf34

Across TCGA pan-cancer cohorts, C8orf34 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated C8orf34 data layer compared with 18 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher C8orf34 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated C8orf34 expression acts as an unfavorable survival marker, although some lineages such as LUSC and UCEC show a favorable association.

BLCA, STAD, and LUAD are the cancer types where C8orf34 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	III,IV	0.239	0.661	<.001	30	view →
STAD	OS	Median	All	0.431	0.695	.006	27	view →
LUAD	DFS	Median	All	0.098	0.768	<.001	9	view →
LUSC	DFS	Median	All	0.924	0.634	.038	2	view →
UCEC	DFS	Median	II,III,IV	0.868	0.437	.043	2	view →
SKCM	OS	Median	III,IV	0.654	0.855	.019	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

C8orf34–BLCA (OS)

Open the BLCA breakdown →